PALI Palisade Bio, Inc.

NASDAQ
$1.45

Palisade Bio, Inc. (PALI) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -29.3% since its last earnings release on August 10, 2026.

Palisade Bio Reported In-line with Estimates
Monday, August 10, 2026 · 4:20 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:20 PM ET
Earnings Whisper
-
vs ($0.06)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.90

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Palisade Bio, Inc.

Palisade Bio is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.